TQB2916
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research[1].
Product Specifications
UNSPSC
12352203
Target
TNF Receptor
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Ba Y, et al. Abstract CT192: A first-in-human phase 1 study of TQB2916, a novel CD40 agonist antibody for advanced malignancies[J]. Cancer Research, 2024, 84 (7_Supplement) : CT192-CT192.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
TNFRSF5/CD40
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1406161-01 0.05 mg (E-Coli)
Recombinant Deinococcus radiodurans Uncharacterized protein DR_B0040 (DR_B0040)
Ask
View Details MBS1406161-02 0.05 mg (Yeast)
Recombinant Deinococcus radiodurans Uncharacterized protein DR_B0040 (DR_B0040)
Ask
View Details 
MBS1406161-03 0.2 mg (E-Coli)
Recombinant Deinococcus radiodurans Uncharacterized protein DR_B0040 (DR_B0040)
Ask
View Details MBS1406161-04 0.5 mg (E-Coli)
Recombinant Deinococcus radiodurans Uncharacterized protein DR_B0040 (DR_B0040)
Ask
View Details MBS1406161-05 0.05 mg (Baculovirus)
Recombinant Deinococcus radiodurans Uncharacterized protein DR_B0040 (DR_B0040)
Ask
View Details MBS1406161-06 0.2 mg (Yeast)
Recombinant Deinococcus radiodurans Uncharacterized protein DR_B0040 (DR_B0040)
Ask
View Details